SEEBRI
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $576.00 | 1 | 0 |
| 2018 | $171,040 | 2,387 | 1,355 |
| 2017 | $49,386 | 1,613 | 1,293 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $114,450 | 58 | 51.8% |
| Food and Beverage | $62,041 | 3,281 | 28.1% |
| Unspecified | $31,395 | 6 | 14.2% |
| Travel and Lodging | $10,738 | 66 | 4.9% |
| Education | $2,379 | 590 | 1.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTI CENTER RANDOMIZED DOUBLE BLIND 52 WEEK STUDY TO ASSESS THE SAFETY OF NVA237 COMPARED TO QAB149 IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD WHO HAVE MODERATE TO SEVERE AIRFLOW LIMITATION | Novartis Pharmaceuticals Corporation | $27,839 | 0 |
| A RANDOMIZED DOUBLE BLIND MULTI CENTER PLACEBO CONTROLLED TWO PERIOD CROSS OVER STUDY TO ASSESS THE EFFECT OF 50UG NVA237 ON EXERCISE ENDURANCE IN PATIENTS WITH MODERATE TO SEVERE COPD | Novartis Pharmaceuticals Corporation | $2,304 | 0 |
| A 52 WEEK TREATMENT RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED WITH OPEN LABEL TIOTROPIUM PARALLEL GROUP STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF NVA237 IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Novartis Pharmaceuticals Corporation | $1,252 | 0 |
Top Doctors Receiving Payments for SEEBRI — Page 10
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Rolla, MO | $81.96 | 2 |
| , DO | Family Medicine | Rolla, MO | $81.96 | 2 |
| , MD | Internal Medicine | Rolla, MO | $81.96 | 2 |
| Monica Flora | — | Toledo, OH | $78.21 | 1 |
| , M.D | Specialist | Fall River, MA | $77.23 | 4 |
| , M.D | Pulmonary Disease | White Hall, AR | $75.88 | 5 |
| , MD | Pulmonary Disease | Tuscaloosa, AL | $74.46 | 8 |
| , MD | Geriatric Medicine | Little Rock, AR | $72.93 | 5 |
| , M.D | Internal Medicine | Selma, AL | $72.62 | 5 |
| , MD | Critical Care Medicine | Columbia, MO | $72.11 | 9 |
| , M.D | Pulmonary Disease | Huntington, WV | $72.01 | 4 |
| , MD | Family Medicine | Decatur, AL | $71.90 | 6 |
| , MD | Internal Medicine | Smithtown, NY | $70.21 | 4 |
| , MD | Internal Medicine | Smithtown, NY | $70.21 | 4 |
| , MD | Pulmonary Disease | Fall River, MA | $69.83 | 3 |
| , D.O | Family Medicine | Ashland, KY | $69.44 | 1 |
| , MD | Family Medicine | Ashland, KY | $69.44 | 1 |
| , D.O | Family Medicine | Ashland, KY | $69.44 | 1 |
| , MD | Family Medicine | Ashland, KY | $69.44 | 1 |
| , D.O | Family Medicine | Ashland, KY | $69.44 | 1 |
| , MD | Family Medicine | Ashland, KY | $69.44 | 1 |
| , M.D | Family Medicine | San Antonio, TX | $69.03 | 5 |
| , M.D | Family Medicine | Evansville, IN | $68.67 | 4 |
| , M.D | Specialist | Saint George, UT | $68.27 | 1 |
| , MD | Internal Medicine | Red Bluff, CA | $68.11 | 5 |
Manufacturing Companies
- Sunovion Pharmaceuticals Inc. $189,607
- Novartis Pharmaceuticals Corporation $31,395
Product Information
- Type Drug
- Total Payments $221,002
- Total Doctors 2,493
- Transactions 4,001
About SEEBRI
SEEBRI is a drug associated with $221,002 in payments to 2,493 healthcare providers, recorded across 4,001 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..
Payment data is available from 2017 to 2019. In 2019, $576.00 was paid across 1 transactions to 0 doctors.
The most common payment nature for SEEBRI is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($114,450, 51.8% of total).
SEEBRI is associated with 3 research studies, including "A MULTI CENTER RANDOMIZED DOUBLE BLIND 52 WEEK STUDY TO ASSESS THE SAFETY OF NVA237 COMPARED TO QAB149 IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD WHO HAVE MODERATE TO SEVERE AIRFLOW LIMITATION" ($27,839).